{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:25:04Z","timestamp":1793377504294,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"GSK","award":["Studies 201790 [NCT03980483] and 201791 [NCT039708"],"award-info":[{"award-number":["Studies 201790 [NCT03980483] and 201791 [NCT039708"]}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1136\/ard-2023-224482","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T11:58:10Z","timestamp":1708084690000},"page":"1516-1526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)"],"prefix":"10.1016","volume":"82","clinical-trial-number":[{"clinical-trial-number":"isrctn03980483","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-1477","authenticated-orcid":false,"given":"Roy M","family":"Fleischmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4978-4072","authenticated-orcid":false,"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain B","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1111-8218","authenticated-orcid":false,"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7766-6167","authenticated-orcid":false,"given":"Peter C","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marguerite","family":"Bracher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Goode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anubha","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara","family":"O'Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Saurigny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorrie A","family":"Schifano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia E","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Millie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E","family":"Weinblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2023-224482_bib1","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/annrheumdis-2017-212862","article-title":"Defining refractory rheumatoid arthritis","volume":"77","author":"Buch","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224482_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224482_bib3","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224482_bib4","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1093\/rheumatology\/kev194","article-title":"Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German Biologics register RABBIT","volume":"54","author":"Gerhold","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224482_bib5","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40744-019-00168-5","article-title":"Patient perceptions of unmet medical need in rheumatoid arthritis: a cross-sectional survey in the USA","volume":"6","author":"Radawski","year":"2019","journal-title":"Rheumatol Ther"},{"key":"10.1136\/ard-2023-224482_bib6","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/acr.24369","article-title":"Systematic literature review of residual symptoms and an unmet need in patients with rheumatoid arthritis","volume":"73","author":"Michaud","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2023-224482_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s12891-016-1192-7","article-title":"Factors predicting pain and early discontinuation of tumour necrosis factor-alpha-inhibitors in people with rheumatoid arthritis: results from the British Society for Rheumatology Biologics register","volume":"17","author":"McWilliams","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1136\/ard-2023-224482_bib8","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.3389\/fimmu.2019.01265","article-title":"Roles of GM-CSF in the pathogenesis of autoimmune diseases: an update","volume":"10","author":"Lotfi","year":"2019","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2023-224482_bib9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrrheum.2015.161","article-title":"Targeting GM-CSF in inflammatory diseases","volume":"12","author":"Wicks","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2023-224482_bib10","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1136\/annrheumdis-2014-205234","article-title":"Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis","volume":"74","author":"Greven","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224482_bib11","doi-asserted-by":"crossref","first-page":"e20190945","DOI":"10.1084\/jem.20190945","article-title":"GM-CSF in inflammation","volume":"217","author":"Hamilton","year":"2020","journal-title":"J Exp Med"},{"key":"10.1136\/ard-2023-224482_bib12","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.4049\/jimmunol.161.7.3639","article-title":"Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice","volume":"161","author":"Campbell","year":"1998","journal-title":"J Immunol"},{"key":"10.1136\/ard-2023-224482_bib13","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1523\/JNEUROSCI.2268-19.2020","article-title":"Granulocyte-macrophage colony stimulating factor as an indirect mediator of Nociceptor activation and pain","volume":"40","author":"Tewari","year":"2020","journal-title":"J Neurosci"},{"key":"10.1136\/ard-2023-224482_bib14","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1172\/JCI113971","article-title":"Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions","volume":"83","author":"Xu","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1136\/ard-2023-224482_bib15","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/rheumatology\/31.10.653","article-title":"Detection of cytokines at the cartilage\/Pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair","volume":"31","author":"Chu","year":"1992","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard-2023-224482_bib16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF00262295","article-title":"Measurement of colony-stimulating factors in synovial fluid: potential clinical value","volume":"14","author":"Bell","year":"1995","journal-title":"Rheumatol Int"},{"key":"10.1136\/ard-2023-224482_bib17","first-page":"39","article-title":"Targeting GM-CSF in rheumatoid arthritis","volume":"34","author":"Avci","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2023-224482_bib18","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/ar318","article-title":"Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the Effector phase of disease","volume":"3","author":"Cook","year":"2001","journal-title":"Arthritis Res"},{"key":"10.1136\/ard-2023-224482_bib19","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/19420862.2015.1099774","article-title":"Molecular basis of in vitro affinity maturation and functional evolution of a neutralizing anti-human GM-CSF antibody","volume":"8","author":"Eylenstein","year":"2016","journal-title":"MAbs"},{"key":"10.1136\/ard-2023-224482_bib20","doi-asserted-by":"crossref","first-page":"e677","DOI":"10.1016\/S2665-9913(20)30229-0","article-title":"Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2B, dose-ranging study","volume":"2","author":"Buckley","year":"2020","journal-title":"The Lancet Rheumatology"},{"key":"10.1136\/ard-2023-224482_bib21","unstructured":"Gupta A, Zecchin C, Watts S, et al. Model informed selection of phase III dosing regimens not fully tested in phase II: anti-GM-CSF mAb, GSK3196165 (Otilimab) in moderate to severe rheumatoid arthritis. American Conference on Pharmacometrics; Orlando, FL, 2019."},{"key":"10.1136\/ard-2023-224482_bib22","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224482_bib23","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.1780350502","article-title":"The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis","volume":"35","author":"Hochberg","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224482_bib24","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224482_bib25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL strategy): a phase 3B\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-224482_bib26","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/art.40803","article-title":"Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic, and safety outcomes from a twenty-four-month, phase III study","volume":"71","author":"van der Heijde","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224482_bib27","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or Adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-224482_bib28","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1016\/S2665-9913(20)30224-1","article-title":"MRI of the joint and evaluation of the granulocyte\u2013macrophage colony-stimulating factor\u2013Ccl17 axis in patients with rheumatoid arthritis receiving Otilimab: a phase 2A randomised mechanistic study","volume":"2","author":"Genovese","year":"2020","journal-title":"The Lancet Rheumatology"},{"key":"10.1136\/ard-2023-224482_bib29","doi-asserted-by":"crossref","first-page":"R83","DOI":"10.1186\/ar3353","article-title":"Pain persists in DAS28 rheumatoid arthritis remission but not in ACR\/EULAR remission: a longitudinal observational study","volume":"13","author":"Lee","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-224482_bib30","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2016-210624","article-title":"A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224482_bib31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13075-019-1879-x","volume":"21","author":"Taylor","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-224482_bib32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/rheumatology\/kex383","article-title":"Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis","volume":"57","author":"Guo","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224482_bib33","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1016\/S2665-9913(21)00145-4","article-title":"Targeting GM-CSF in rheumatological conditions: risk of PAP","volume":"3","author":"Rooney","year":"2021","journal-title":"The Lancet Rheumatology"},{"key":"10.1136\/ard-2023-224482_bib34","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1016\/S2665-9913(20)30352-0","article-title":"The efficacy and safety of targeting GM-CSF in arthritis","volume":"2","author":"Bykerk","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2023-224482_bib35","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with Infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-224482_bib36","doi-asserted-by":"crossref","first-page":"8652","DOI":"10.1038\/s41598-018-26984-3","article-title":"GM-CSF targeted Immunomodulation affects host response to M. Tuberculosis infection","volume":"8","author":"Benmerzoug","year":"2018","journal-title":"Sci Rep"},{"key":"10.1136\/ard-2023-224482_bib37","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/1756-185X.13395","article-title":"Pharmacodynamic biomarkers and differential effects of TNF- and GM-CSF-targeting biologics in rheumatoid arthritis","volume":"22","author":"Guo","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1136\/ard-2023-224482_bib38","doi-asserted-by":"crossref","first-page":"2101870","DOI":"10.1183\/13993003.01870-2021","article-title":"A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)","volume":"61","author":"Patel","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1136\/ard-2023-224482_bib39","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/annrheumdis-2012-202450","article-title":"Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224482_bib40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/art.40323","article-title":"A randomized phase IIb study of mavrilimumab and golimumab in rheumatoid arthritis","volume":"70","author":"Weinblatt","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224482_bib41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/14397595.2014.896448","article-title":"Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from a phase IIa study","volume":"25","author":"Takeuchi","year":"2015","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard-2023-224482_bib42","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-224482_bib43","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2023-224482_bib44","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-224482_bib45","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40744-019-00179-2","article-title":"Physical and emotional burden of rheumatoid arthritis: data from RA matters, a web-based survey of patients and healthcare professionals","volume":"6","author":"Alten","year":"2019","journal-title":"Rheumatol Ther"},{"key":"10.1136\/ard-2023-224482_bib46","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5665\/sleep.1742","article-title":"Sleep loss exacerbates fatigue, depression, and pain in rheumatoid arthritis","volume":"35","author":"Irwin","year":"2012","journal-title":"Sleep"},{"key":"10.1136\/ard-2023-224482_bib47","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s41687-021-00318-w","article-title":"Qualitative and Psychometric approaches to evaluate the PROMIS pain interference and sleep disturbance item banks for use in patients with rheumatoid arthritis","volume":"5","author":"Becker","year":"2021","journal-title":"J Patient Rep Outcomes"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724083614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724083614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2023-224482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T03:35:14Z","timestamp":1739504114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724083614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0003496724083614"],"URL":"https:\/\/doi.org\/10.1136\/ard-2023-224482","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-224482","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}